What services does JCC Group provide for pharmaceutical and biologics manufacturers?

JCC Group offers end-to-end regulatory consulting services for pharmaceutical and biologics companies, including 21 CFR Part 211 cGMP compliance, Quality Management System (QMS) design, validation strategy, FDA inspection readiness, supplier qualification, data integrity assessments, and harmonization with ICH international standards (Q7, Q8, Q9, Q10, and Q11). Our consultants partner with clients across the full product lifecycle — from facility start-up and clinical-stage manufacturing through commercial production and post-approval changes.

What types of companies does JCC Group work with?

We support a broad spectrum of clients, including emerging biotech startups, contract manufacturers (CMOs/CDMOs), mid-size pharmaceutical companies, global drug manufacturers, biologics and cell & gene therapy developers, and international manufacturers exporting to the U.S. market. Whether you are launching your first product or managing a multi-site global operation, our services scale to fit your needs.

What is 21 CFR Part 211, and who must comply?

21 CFR Part 211 establishes the FDA's Current Good Manufacturing Practice (cGMP) requirements for finished pharmaceuticals. It applies to any company involved in manufacturing, processing, packaging, labeling, or holding human and veterinary drug products distributed in the United States — including drug substance and drug product manufacturers, contract facilities, and repackagers.

How does JCC Group help companies achieve 21 CFR Part 211 compliance?

We provide comprehensive support including cGMP gap assessments, QMS design and implementation, SOP and documentation development, equipment qualification (IQ/OQ/PQ), process and cleaning validation, quality control laboratory compliance, change control programs, CAPA systems, and mock FDA inspections. Our team builds compliance programs tailored to your operations — not generic templates.

Does JCC Group support biologics manufacturers under 21 CFR Part 211?

Yes. While biologics are also governed by 21 CFR Part 600-series regulations, Part 211 still applies to many aspects of biologic drug product manufacturing. We support biologics manufacturers across monoclonal antibodies, recombinant proteins, vaccines, cell and gene therapies, and biosimilars — addressing both small-molecule and large-molecule complexities.

What are ICH guidelines, and why do they matter?

The International Council for Harmonisation (ICH) develops globally recognized standards for pharmaceutical quality, safety, and efficacy. Compliance with ICH guidelines — especially Q7 (API GMP), Q8 (Pharmaceutical Development), Q9 (Quality Risk Management), Q10 (Pharmaceutical Quality System), and Q11 (Drug Substance Development) — is essential for companies seeking global market access and harmonized regulatory approval across the U.S., EU, Japan, and other ICH regions.

How does JCC Group help companies align with ICH standards?

Our consultants integrate ICH principles into every aspect of our consulting work. We design Pharmaceutical Quality Systems aligned with ICH Q10, implement quality risk management frameworks per ICH Q9, support development activities under Q8/Q11, and ensure API manufacturing aligns with ICH Q7 — enabling clients to meet both FDA expectations and global harmonized requirements simultaneously.

Can JCC Group build a Quality Management System (QMS) from scratch?

Absolutely. We design and implement complete Quality Management Systems for new facilities, startups, and companies transitioning from clinical-stage to commercial manufacturing. Our QMS deliverables include Quality Manuals, SOPs, work instructions, forms, Master Production Records, Batch Production Records, change control systems, and integrated documentation control platforms.

Does JCC Group provide ongoing QMS maintenance and support?

Yes. Beyond initial implementation, we offer long-term advisory services to keep your QMS current with evolving regulations, support periodic management reviews, conduct internal audits, manage CAPA effectiveness checks, and provide regulatory intelligence updates. Many clients engage us as their long-term regulatory partner rather than a one-time consultant.

What happens during a mock FDA inspection conducted by JCC Group?

Our mock inspections replicate real FDA methodology — including facility walkthroughs, document reviews, employee interviews, and front-room/back-room dynamics. We assess your operations against 21 CFR Part 211, your QMS, and applicable ICH standards, then deliver a detailed report with prioritized findings, root cause insights, and clear remediation recommendations.

Can JCC Group help if we received a Form 483 or FDA Warning Letter?

Yes — rapid-response remediation is one of our core specialties. Our team conducts immediate root cause investigations, develops comprehensive CAPA plans, drafts written responses that meet FDA expectations, and manages the remediation process from start to finish. We have helped clients successfully close significant findings and restore compliance under tight deadlines.

Tobacco Consumer Perception Research - J&J Consulting Group- FDA Regulatory Compliance

Marketing Research and Consumer Perception Studies for Tobacco Products

PMTA-Grade Behavioral Science from J&J Compliance Consulting Group (JJCC Group)

For any company seeking to legally market a new tobacco product in the United States, behavioral research is not a marketing luxury; it is a regulatory necessity. Under Section 910 of the Federal Food, Drug, and Cosmetic Act and the implementing regulations at 21 CFR Part 1114, the U.S. Food and Drug Administration will only issue a marketing order when an applicant demonstrates that permitting the product to enter the market is “appropriate for the protection of the public health” (the APPH standard). Establishing that standard is impossible without rigorous evidence of how real people perceive, understand, and intend to use the product. This is precisely the domain of marketing research and consumer perception science, and it is a discipline in which J&J Compliance Consulting Group (JJCC Group) operates as a recognized authority.

The FDA evaluates a Premarket Tobacco Product Application (PMTA) on the totality of the evidence, weighing risks to users against benefits to the population as a whole, including non-users and youth. Tobacco Product Perception and Intention (TPPI) studies sit at the heart of this analysis. They tell the Agency whether a product is likely to encourage initiation among never-users, whether it may prompt relapse among former users, whether it could drive dual- or poly-use, and whether the labeling and marketing communicate risk accurately. A PMTA submitted without methodologically sound perception research is an application exposed to a refuse-to-accept or refuse-to-file action, or to denial on the merits. JJCC Group designs and executes this research to FDA specifications, positioning each submission for success.

Why the PMTA Requires Consumer Perception Research

The statutory APPH standard forces the FDA to look beyond a product’s chemistry and engineering. A tobacco product may be manufactured to flawless specifications and still fail review if its real-world reception undermines public health. To resolve that question, the Agency relies on behavioral evidence drawn directly from the intended population. The FDA’s 2022 final guidance, “Principles for Designing and Conducting Tobacco Product Perception and Intention Studies,” codifies its current thinking on how this research should be performed, and JJCC Group builds every study to align with it.

Consumer perception research answers the questions an FDA reviewer must address before granting an order:

Risk perception: Do consumers accurately understand the relative and absolute risks of the product, particularly where reduced-harm impressions could form?
Use intention: Are never-users, including youth and young adults, likely to be drawn to initiate, or is appeal concentrated among existing adult users seeking to switch from more harmful products?
Label and advertising comprehension: Do the labeling, warnings, and promotional stimuli convey the intended meaning without creating false or misleading impressions?
Relapse and poly-use potential: Does the product risk pulling former users back into tobacco use or encouraging simultaneous use of multiple products?

Because the FDA recommends that perception studies compare the proposed product against products currently on the market, not merely against combustible cigarettes, and that they address null findings and statistical power directly, the research demands genuine behavioral-science expertise. This is where many applications falter, and where JJCC Group delivers decisive value.

The JJCC Group Approach: Authoritative, FDA-Aligned Research

JJCC Group brings subject-matter command of both the regulatory framework and the behavioral-science methodology that underpins a defensible PMTA. We do not treat consumer perception research as a checkbox; we engineer it as scientific evidence built to withstand FDA review and, where applicable, scrutiny by the Tobacco Products Scientific Advisory Committee (TPSAC). Our methodology mirrors the structure the Agency expects, from hypothesis through final report module.

Initial Assessment and Research Strategy

Every engagement begins with a comprehensive assessment of the product profile, existing data, and any prior research. We define the new tobacco product precisely, identify the comparator products required by FDA, articulate the research questions and study hypotheses, and determine which TPPI constructs, perceptions, understanding, and intentions, must be measured to support the APPH determination for that specific product category, whether ENDS, cigars, smokeless, or novel formats.

Study Design and Methodology

JJCC Group designs studies, qualitative, quantitative, or mixed-method, that satisfy FDA’s scientific principles. This includes defining the target population and relevant subgroups (current users, former users, never-users, youth-vulnerable segments), establishing representative sampling frames, selecting validated measures from the peer-reviewed literature where available, and developing scientifically justified new measures where necessary. We specify study outcomes from the hypotheses, power the study appropriately, and pre-plan analyses so that null findings can be interpreted with confidence rather than dismissed.

Stimuli Development and Realistic Representation

Where a study uses labels, labeling, or advertising as stimuli, FDA requires a clear statement of whether those stimuli represent the advertising the applicant intends to use. JJCC Group develops compliant, representative stimuli and documents their relationship to planned commercial communications, closing a gap that frequently triggers FDA deficiencies.

Data Collection and Quality Controls

We oversee recruitment, screening, and data collection through controlled protocols with documented quality assurance, ensuring data integrity that satisfies the same ALCOA principles the FDA applies across regulated industries. Rigorous data-quality controls protect against the low-power, poor-measure pitfalls the Agency explicitly cautions against.

Analysis, Reporting, and PMTA Module Assembly

JJCC Group conducts rigorous statistical and qualitative analysis, then drafts a full study report and assembles it into the appropriate PMTA module with the supporting documentation FDA expects. We frame findings in terms of the APPH standard, connecting the behavioral evidence directly to the public-health argument the reviewer must evaluate.

Post-Submission Support and FDA Engagement

Our work does not end at submission. JJCC Group tracks the application, prepares responses to FDA information requests and deficiency letters, and supports any postmarket TPPI obligations that accompany a marketing granted order, providing continuity from research design through authorization and beyond.

Tailored Research Across Tobacco Product Categories

The perception questions that matter most shift with the product type, and JJCC Group calibrates each study accordingly:

Electronic Nicotine Delivery Systems (ENDS) and e-cigarettes: Emphasis on youth appeal, flavor perception, switching from combustibles, and misperceptions of harmlessness, the areas FDA scrutinizes most heavily in this category.
Cigars and cigarillos: Focus on appeal among young adults, perceptions of relative risk versus cigarettes, and comprehension of warnings.
Smokeless and oral nicotine products: Examination of harm-reduction perceptions, initiation risk, and dual-use with combustibles.
Heated tobacco and novel formats: Assessment of reduced-exposure impressions and the accuracy of consumer understanding relative to marketing.

Why JJCC Group Is the Authority Manufacturers Trust

Obtaining a marketing order is a high-stakes, evidence-intensive undertaking, and the consumer perception component is among the most technically demanding elements of the entire PMTA. JJCC Group combines deep command of 21 CFR Part 1114, the APPH standard, and the FDA’s TPPI guidance with hands-on behavioral-research capability and the regulatory documentation discipline the Agency demands. We guide clients through every stage with precision and a personalized approach, preparing scientific studies, drafting reports, assembling PMTA modules, and providing post-submission support to track applications and respond to FDA inquiries. The result is research that is not merely completed, but strategically positioned for authorization, giving manufacturers a clear, evidence-based view of how the public perceives their product and a submission engineered to satisfy the FDA’s public-health mandate.